Friday, July 1, 2016

Tuesday Features

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Frank Condella, President and CEO Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella,... [Read more of this feature]


Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

CEO, Dan Legault Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage... [Read more of this feature]


S1 Biopharma to start Phase 2b study in female HSDD by yearend

S1 Biopharma to start Phase 2b study in female HSDD by yearend

Nick Sitchon, CEO Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with a second therapy, Orexa, for male HSDD. “HSDD is characterized by a lack or absence of sexual fantasies and desire for sexual... [Read more of this feature]


More Posts From Tuesday Features

Briefs

JMP resumes coverage of AtriCure

JMP resumes coverage of AtriCure

JMP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday. “AtriCure is well positioned, in our view, to further develop and penetrate several large opportunities that are currently underserved in and around atrial fibrillation (AF),” writes analyst... [Read more of this brief]


Rodman starts Catalyst Biosciences at buy

Rodman starts Catalyst Biosciences at buy

Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which... [Read more of this brief]


Rodman starts OpGen at buy

Rodman starts OpGen at buy

Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest generation of its fluorescence in situ hybridization (FISH) platform, are differentiated from competitors in that they utilize... [Read more of this brief]


HCW starts Vascular Biogenics at buy

HCW starts Vascular Biogenics at buy

H.C. Wainwright has launched coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and 12-month price target of $11. The stock closed at $4.10 on Tuesday. Vascular Biologics, also known as VBL Therapeutics or VBL, is developing a novel anti-angiogenesis therapy for the treatment of solid tumors. Anti-angiogenesis therapies are currently... [Read more of this brief]


Rodman starts NeuroMetrix at buy

Rodman starts NeuroMetrix at buy

Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and arthritis. “In our view,... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+